

Listing of the Claims

1-33. (canceled)

34. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein;

the light chain variable region comprises:

a CDRL1 amino acid sequence SEQ ID NO:5;

a CDRL2 amino acid sequence SEQ ID NO:13; and

a CDRL3 amino acid sequence SEQ ID NO:19, and the heavy chain variable region comprises:

a CDRH1 amino acid sequence of SEQ ID NO:25;

a CDRH2 amino acid sequence of SEQ ID NO:39; and

a CDRH3 amino acid sequence of SEQ ID NO:57;

35-39. (canceled)

40. (withdrawn) A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein;

the light chain variable region comprises:

a CDRL1 amino acid sequence of SEQ ID NO:5;

a CDRL2 amino acid sequence of SEQ ID NO:13; and

a CDRL3 amino acid sequence of SEQ ID NO:19, and

the heavy chain variable region comprises:

a CDRH1 amino acid sequence of SEQ ID NO:25;

a CDRH2 amino acid sequence of SEQ ID NO:39; and

a CDRH3 amino acid sequence of SEQ ID NO:57;

41. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.
42. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (k_{off}) for human CD20 of $5.0 \times 10^{-4} \text{ s}^{-1}$ or less.
43. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.
44. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of $2.5 \times 10^{-4} \text{ s}^{-1}$ or less.
45. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of $5.0 \times 10^{-5} \text{ M}^{-1} \text{ s}^{-1}$ or greater.
46. (withdrawn) The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.
47. (withdrawn) The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.
48. (previously presented) The composition of Claim 34, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:59 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:61.

49. (withdrawn) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

- a CDRL1 amino acid sequence of SEQ ID NO:3;
- a CDRL2 amino acid sequence of SEQ ID NO:11; and
- a CDRL3 amino acid sequence SEQ ID NO:21, and

the heavy chain variable region comprises:

- a CDRH1 amino acid sequence of SEQ ID NO:23;
- a CDRH2 amino acid sequence of SEQ ID NO:31; and
- a CDRH3 amino acid sequence of SEQ ID NO:45.

50. (withdrawn) The composition of Claim 49, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:63 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:65.

51. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain amino acid sequence of SEQ ID NO: 67 and a heavy chain amino acid sequence of SEQ ID NO: 69.